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Cystic Changes in Intraabdominal
Extrahepatic Metastases from
Gastrointestinal Stromal Tumors Treated
with Imatinib
Objective: This study was undertaken for the purpose of describing the CT
features of intra-abdominal extra-hepatic metastases from gastrointestinal stro-
mal tumors in patients who were treated with imatinib.
Materials and Methods: Eleven patients with intra-abdominal extra-hepatic
metastases from gastrointestinal stromal tumors, who were treated with imatinib
between May 2001 and December 2003, were included in this study. The clinical
findings and CT scans were retrospectively reviewed. The metastatic lesions
were assessed according to the location, size (greatest diameter), attenuation,
and the enhancing pattern before and after imatinib treatment.
Results: Prior to the treatment, the sizes and attenuation values of the
metastatic lesions ranged from 5 to 20 cm and from 63 to 131 H, respectively.
The metastatic lesions showed a heterogeneous enhancement pattern on the
contrast-enhanced CT scans. After the treatment, the metastatic lesions became
smaller in all 11 patients, and the corresponding attenuation value ranged from
15 to 51 H. The metastatic lesions became homogeneous and cystic in appear-
ance on the follow-up CT scans, mimicking ascites.
Conclusion: Intra-abdominal extra-hepatic metastases of patients with gas-
trointestinal stromal tumors treated with imatinib may appear as well-circum-
scribed cystic lesions on contrast-enhanced CT. These metastases are likely to
become smaller and resemble ascites, but may persist indefinitely on the follow-
up CT.
astrointestinal stromal tumors, formerly classified as leiomyomas or
leiomyosarcomas, constitute the most common form of mesenchymal
tumor in the gastrointestinal tract, with the stomach being the most
common site of origin (1). The diagnosis of these tumors became feasible through the
application of CD117 immunohistochemistry, which allows these neoplasms to be
distinguished from leiomyomas or leiomyosarcomas (2). Moreover, the recently
developed KIT-tyrosine kinase inhibitor (STI 571, imatinib [Gleevec], Novartis,
Basel, Switzerland) has dramatically improved the treatment of gastrointestinal
stromal tumors (3).
The radiologic findings of gastrointestinal stromal tumors were recently described in
the radiologic literature (1, 4 8), and are ostensibly similar to those of the previously
described leiomyomas or leiomyosarcomas (9). The characteristic features of this
disease are its recurrence at the primary site and the presence of metastases, primarily
in the liver and the peritoneum (4). Recently, it was reported that the hepatic
metastases in patients treated with imatinib resembled cystic lesions (10 12). In line
with these observations, our findings indicate that when gastrointestinal stromal
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rtumors are treated with imatinib, the intra-abdominal
extra-hepatic metastases come to have a homogeneous or
almost homogeneous low density, simulating cystic masses
or ascites on CT.
MATERIALS AND METHODS
From May 2001 to December 2003, 11 patients with
intra-abdominal extra-hepatic metastases from gastroin-
testinal stromal tumor were treated with imatinib. Their
mean age was 50 years, ranging from 34 to 68 years, and
all were men. The mean time between the initial diagnosis
of the gastrointestinal stromal tumor and the diagnosis of
metastases was 19 months (range, 7 38 months). The
primary sites were the stomach (n=5), the small bowel
(n=3), the rectum (n=1), and the mesentery (n=2). In all
patients, the primary tumors were removed by curative
surgery. The presence of metastatic lesions was confirmed
by biopsy (n=5) or radiologic studies and clinical follow-up
(n=6). The criterion for the diagnosis of metastasis was the
presence of new lesions detected in the follow-up CT scan,
which were not detected in the initial CT scan and which
changed in size on the follow-up CT scan after imatinib
treatment. In all patients, CD117 expression in the primary
gastrointestinal stromal tumors (n=6) or metastatic lesions
(n=5) was proved by immunohistochemical studies. All
patients were treated with the oral administration of 400
mg of imatinib daily. The clinical symptoms, duration of
imatinib therapy, and CT scan reports were reviewed. The
institutional review board at our hospital did not require
approval or informed patient consent for the review of the
medical records and images.
All patients underwent CT scans prior to the administra-
tion of imatinib and 4 10 weeks after the initiation of the
imatinib therapy. Ten patients underwent two or more
follow-up CT scans 4 22 months after the initiation of the
treatment with imatinib. The CT scan data were available
on a picture archiving and communications system (PACS;
Marotech, Seoul, Korea) for all patients. The CT scans
were performed using a Somatom Plus-4 (Siemens Medical
Systems, Erlangen, Germany), a HiSpeed Advantage
scanner (General Electric Medical Systems, Milwaukee,
WI), or a MX8000 four-detector row CT scanner (Philips
Medical Systems, Cleveland, OH). Each patient received
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Fig. 1. A 34-year-old man with peritoneal seeding and liver
metastases after resection of gastrointestinal stromal tumor of the
duodenum.
A. CT scan before treatment shows multiple heterogeneous
masses (82 H) (M) compressing inferior vena cava (arrowhead)
and superior mesenteric vein (arrow). Metastatic lesion in liver
(curved arrow).
B. CT scan obtained after 8 weeks of treatment with imatinib
shows peritoneal and hepatic metastases that have decreased in
size and density (35 H). Note the decompressed inferior vena cava
and superior mesenteric vein and shrunk metastatic lesions in the
liver.
C. CT scan obtained 2 months after stopping imatinib therapy
shows increased size and density of peritoneal and hepatic
metastases. After resumption of imatinib therapy, the metastatic
lesions showed cystic changes again (now shown).
C120 mL of a nonionic contrast material (Iopromide,
Ultravist 370; Schering Korea, Seoul, Korea) through an
18-gauge angiographic catheter inserted into a forearm
vein. The contrast material was injected at a rate of 2.5
mL/sec using an automatic injector. In the case of the
single-detector scanner, a helical CT scan was performed
with the following parameters: 5 7 mm collimation, 1:1
table pitch, and 5 7 mm reconstruction intervals. In the
case of the MX8000 scanner, the parameters were 2.5 mm
detector collimation, 20 mm/sec table speed, 5 mm slice
thickness, and a 5 mm reconstruction interval. The delay
between the contrast material administration and scanning
was 55 70 seconds.
Two radiologists reviewed all of the CT scans retrospec-
tively, and the final interpretations were reached by
consensus. All images were reviewed on a 2,000 2,000
PACS monitor. The presence of the metastatic lesion and
its size before and after the imatinib treatment were
compared. The metastatic lesions were assessed according
to their location, size (greatest diameter), attenuation, and
enhancing pattern. If multiple metastatic lesions were
detected, the largest lesion was recorded. For the objective
analysis, the CT attenuation value was measured in a
circular region of interest with a diameter of 10 mm. The
CT attenuation value was measured three times by a single
radiologist and the mean value was recorded. In the case of
a heterogeneous mass, the CT attenuation value was
measured in the solid portion of the tumor. The CT attenu-
ation value before and after the imatinib treatment was
compared using the paired t-test. Statistical analyses were
performed using a computer software package (SPSS,
version 10.0; SPSS, Chicago, Ill). A p value of less than .05
was considered to indicate a statistically significant differ-
ence.
RESULTS
The clinical and radiologic findings are summarized in
Table 1. One patient (patient 3) was lost to follow-up after
1 month of imatinib therapy. Two patients (patients 2 and
Kim et al.
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Fig. 2. A 68-year-old man with peritoneal seeding after resection of
gastrointestinal stromal tumor of the stomach.
A. CT scan before treatment shows 15 13 cm heterogeneous
metastatic lesion (81 H) (G) in left subphrenic space. Note small
metastatic nodule (arrow) in right subphrenic space and ascites (15
H).
B. CT scan obtained after 8 weeks of treatment with imatinib
shows metastatic lesion (G) that has decreased in size to 8 6 cm
and is cyst-like in appearance lesion (28 H) around spleen (S).
Note the disappearance of the ascites.
C. CT scan obtained after 13 months of treatment with imatinib
shows 5 3.5 cm cystic lesion (20 H).
C11) stopped imatinib therapy 10 and 11 months, respec-
tively, after the initiation of the treatment. The remaining
8 patients were under imatinib therapy for periods ranging
from 4 to 22 months at the time this article was written.
On the contrast-enhanced CT, the metastatic lesions
were detected in the peritoneal cavity (n=9), and at the
surgical bed of the primary site (n=2). In four patients,
metastasis was also detected in the liver. Prior to the
treatment, the mean size of the metastatic lesions was 10.4
4.9, ranging from 5 to 20 cm, and they showed a hetero-
geneous enhancement pattern on the contrast-enhanced
CT scans.
After the treatment, the mean size of the metastatic
lesions was 5.8 3.6, ranging from 3 to 15 cm, on the first
follow-up CT scan, showing a reduction in size for all 11
patients. On the first follow-up CT scan, the attenuation of
the metastatic lesions was homogeneous in eight patients
(Figs. 1 and 2), and heterogeneous in three patients (Fig.
3). In cases of peritoneal seeding, the metastatic lesions
developed a cystic appearance, mimicking ascites (Figs. 2
and 3). In reviewing the original CT reports, it was found
that the cystic change of the tumor was described as ascites
or fluid collection in three patients.
Prior to the treatment, the mean attenuation value of the
metastatic lesions was 83 20 H, ranging from 63 to 131
H. On the first follow-up CT scan, the mean attenuation
value was 34 13 H, ranging from 15 to 51 H. This differ-
ence in the mean CT attenuation value was statistically
significant (p < 0.01).
On the subsequent CT scans, the metastatic lesions
became smaller, homogeneous and cystic during imatinib
therapy. However, they did not disappear completely and
were always detected throughout the study in all patients.
In two patients who showed a heterogeneous enhancement
pattern on the first follow-up CT scan, the metastatic
lesions became homogeneous on the second follow-up CT
scan obtained 3 and 4 months, respectively, after the initia-
tion of treatment.
Two patients (patients 2 and 11) stopped imatinib
therapy 10 and 11 months, respectively, after the initiation
of the treatment. The disease was found to have
progressed in these 2 patients 11 and 2 months, respec-
tively, after the termination of the treatment, with the
metastatic lesions increasing in size and attenuation, and
showing a heterogeneous enhancement pattern on the CT
scans (Fig. 1C). These two patients resumed imatinib
therapy, and their metastatic lesions subsequently became
smaller and homogeneous on the follow-up CT scans.
DISCUSSION
Conventional chemotherapeutic agents are rarely
effective against gastrointestinal stromal tumors. The new
chemotherapeutic agent, imatinib, has been applied and
the results are extremely encouraging. The rationale
behind imatinib treatment for gastrointestinal stromal
tumors lies in the fact that the KIT (encodes the human
homolog of the proto-oncogene c-kit) gene mutation has
been detected frequently in gastrointestinal stromal
tumors. This mutation induces the constitutive activation
of the tyrosine kinase receptor, causing the proliferation of
tumor cells (2). Imatinib is highly effective in bringing
about a reduction in KIT tyrosine kinase activity.
Gastrointestinal stromal tumors frequently spread to the
liver and the peritoneum (4). On the CT scan of the portal
venous phase, the metastases within the liver are usually
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Fig. 3. A 52-year-old man with peritoneal seeding after resection of gastrointestinal stromal tumor of the mesentery.
A. CT scan before treatment shows multiple peritoneal implants (arrows) in both paracolic gutters.
B. CT scan obtained after 4 weeks of treatment with imatinib shows that the metastatic lesions in the right paracolic gutter have some
solid components, while that in the left paracolic gutter resembles ascites.
ABheterogeneous and peripherally enhanced, similar to
primary tumors (4). The low attenuation in the center of
these metastatic lesions often indicates the presence of
necrosis in the center of the solid mass. The peripheral
enhanced portion represents viable solid tumor. Peritoneal
metastasis shows a CT appearance similar to that of
metastasis in the liver.
In the peritoneum, metastatic lesions treated with
imatinib may appear as ascites or fluid collection. In
reviewing the original CT reports, we found that the cystic
change of the tumor was described as ascites or fluid
collection in three patients. Although long-term follow-up
is needed, metastatic lesions in the peritoneum gradually
decrease in size, although they may persist for months or
years, which is not the case for ascites. The density of the
metastases decreased to 15 51 H on the first CT scan after
the treatment and then to 15 28 H on the follow-up CT
scan, which is close to that of ascites. Metastases can be
distinguished from ascites by reviewing the change in the
attenuation value and the previous CT scan. Ideally, the
scans should be interpreted by a radiologist who is familiar
with scans of peritoneal metastases from gastrointestinal
stromal tumors following imatinib treatment, in order to
avoid the underestimation of the extent of the tumors.
The mechanism that induces the cystic change after
imatinib treatment is not clear. In several reported cases,
histological examination of the tumors treated with
imatinib showed areas with extensive necrosis, hyalinized
areas with sparse, scattered tumor cells containing small,
condensed nuclei and areas with viable tumor cells (10
12).
The optimal duration of the treatment is not yet known
(13). It is not clear whether viable tumor cells with
malignant potential persist within the cystic lesions and,
consequently, the continuous maintenance of imatinib
treatment is required. In this study, two patients whose
metastatic lesions became small and cystic after imatinib
therapy, experienced aggravation of metastasis after
termination of the imatinib treatment.
Traditionally, the response to cancer treatment in solid
tumors is evaluated by subsequent clinical or radiological
assessments, and is defined as a significant decrease in the
measurable tumor dimensions. A reduction in the viable
tumor cell fraction, however, does not always result in a
volume reduction, since tumor tissue can be replaced by
necrotic or fibrotic tissue, and morphological images are
often unable to differentiate between these different tissue
types. In recent years, metabolic imaging with positron
emission tomography (PET) has become increasingly
important in cancer management. Although the perfor-
mances of PET and CT are comparable in terms of the
process of staging before the initiation of imatinib therapy,
PET can evaluate the tumor response as early as 1 week
after the start of treatment, preceding the CT response by
several weeks (14). Treatment-induced changes resulting in
tumor cell death or growth arrest should therefore result in
a subsequent reduction in glucose uptake, making this
technique a sensitive and early marker for response
evaluation.
There are several limitations to this study. First, this was
a retrospective review of cases collected over a number of
years for which CT scans were performed irregularly,
depending on the condition of the patients. Second,
unenhanced images were not obtained in all patients, and
it is unclear whether or not any subtle enhancement
changes are present in the metastatic lesions. Third, we did
not provide any pathologic correlation in any of the cases.
Pathologic correlation with the radiologic findings for
metastatic lesions is helpful for clinicians as well as for
radiologists.
In conclusion, after treatment with imatinib, responsive
intra-abdominal extra-hepatic metastases of gastrointesti-
nal stromal tumors appear as well-defined cystic lesions on
contrast-enhanced CT. These metastases become smaller
and resemble ascites, but may be detected for a long time
on the follow-up CT scans.
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